Michael P. Dillon - 27 Jul 2021 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role
SVP, Chief Scientific Officer
Signature
/s/ Jason Throne, as Attorney-in-Fact for Michael P. Dillon
Issuer symbol
IDYA
Transactions as of
27 Jul 2021
Net transactions value
-$195,310
Form type
4
Filing time
29 Jul 2021, 17:18:17 UTC
Previous filing
08 Jul 2021
Next filing
11 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $34,600 +5,000 +5.1% $6.92 103,789 27 Jul 2021 Direct
transaction IDYA Common Stock Options Exercise $21,550 +5,000 +4.8% $4.31* 108,789 27 Jul 2021 Direct
transaction IDYA Common Stock Sale $251,460 -10,000 -9.2% $25.15 98,789 27 Jul 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (right to buy) Options Exercise $0 -5,000 -11% $0.000000 39,500 27 Jul 2021 Common Stock 5,000 $6.92 Direct F3
transaction IDYA Stock Option (Right to Buy) Options Exercise $0 -5,000 -6.9% $0.000000 67,735 27 Jul 2021 Common Stock 5,000 $4.31 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades in prices ranging from $24.95 to $25.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F4 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.